Carlisle Companies (NYSE:CSL – Get Free Report) is projected to announce its earnings results after the market closes on Tuesday, February 4th. Analysts expect the company to announce earnings of ...

KOCHI: In a move to revitalise India’s shipbuilding industry, the latest budget has set its sights on enhancing the nation’s ...

Shares of Carlisle Companies Incorporated (NYSE:CSL – Get Free Report) have been assigned an average rating of “Moderate Buy” from the five research firms that are currently covering the stock, ...

RBC Capital analyst Craig Wong-Pan maintained a Hold rating on CSL (CMXHF – Research Report) on January 29 and set a price target of A$286.00.

Australia’s Therapeutic Goods Administration (TGA) has approved CSL Ltd.’s Andembry (garadacimab) for preventing recurrent ...

Goldman Sachs analyst Davinthra Thillainathan maintained a Buy rating on CSL (CMXHF – Research Report) today and set a price target of ...

Goldman Sachs is saying good things about this blue chip stock. The post 1 big reason to buy CSL shares now appeared first on ...

Learn More Now could be the time to pounce on CSL Ltd (ASX: CSL) shares. That's the view of analysts at Goldman Sachs, which have just initiated coverage on the company. CSL is a global ...

Getty Images / Thomas Barwick A master limited partnership (MLP) is an unusual investment that combines the tax benefits of a limited partnership (LP) with the liquidity of a common stock.

On Thursday, Goldman Sachs (NYSE:GS) began coverage on shares of CSL Ltd (OTC:CSLLY). (CSL:AU) (OTC: CMXHF) with a Buy rating and a price target set at AUD325.40. The new target indicates a potential ...

ARCT Arcturus Therapeutics Holdings Inc.